Pediatric Asthmatic Medications: Comparison
View Latest Version
Please note this is a comparison between Version 3 by Beatrix Zheng and Version 2 by Beatrix Zheng.

Asthma is a respiratory condition often stemming from childhood, characterized by difficulty breathing and/or chest tightness. Current treatment options for both adults and children include beta-2 agonists, inhaled corticosteroids (ICS), and leukotriene modifiers (LTM). Despite recommendations by the Global Initiative for Asthma, a substantial number of patients are unresponsive to treatment and unable to control symptoms. Pharmacogenomics have increasingly become the front line of precision medicine, especially with the recent use of candidate gene and genome- wide association studies (GWAS). Screening patients preemptively could likely decrease adverse events and therapeutic failure. However, research in asthma, specifically in pediatrics, has been low. Although numerous adult trials have evaluated the impact of pharmacogenomics and treatment response, the lack of evidence in children has hindered progress towards clinical application. 

  • pediatric asthma
  • pharmacogenomics
  • beta-2 receptors
  • inhaled corticosteroids
  • leukotriene modifiers

1. Introduction

Asthma is a multifactorial respiratory condition characterized by the narrowing of one’s airways and affects over 300 million people, including 7% of children in the US [1]. Approximately 90% of all asthma cases stem from childhood [2], with the biggest burden on the quality of life in children ages 10–14 [3]. Symptoms such as difficulty breathing, shortness of breath, wheezing, tightness of the chest, etc. are early markers to suspect and diagnose asthma. Left untreated or uncontrolled, many childhood asthma cases can continue into adulthood, decreasing quality of life and potentially increasing the risk of developing chronic obstructive pulmonary disease (COPD). Managing asthma alone accounts for approximately $80 billion spent annually on healthcare in the US [4]. In 2013, children between the ages of 5–17 in the US missed nearly 13 million days of school, an increase from the 10.4 million days in 2008 [5]. With a projected 100 million additional asthma cases by 2025 [6], the importance of finding appropriate treatment and gaining control of symptoms is even more crucial. Common treatment options for asthma are bronchodilators, inhaled corticosteroids (ICS), and leukotriene modifiers (LTM). Goals of therapy include providing symptomatic relief by optimizing airway function, reducing future exacerbations, and minimizing adverse effects from medications. According to the 2021 Global Initiative for Asthma (GINA) guidelines, initial pediatric treatment recommendations include using short acting beta agonists (SABA) and/or low doses of ICS as the first-line of therapy. In situations where symptoms are not adequately controlled, these guidelines provide recommendations when considering additional medications [7].
Despite this, up to 70% of patients are still unable to find proper relief [8]. Improper diagnoses and lack of adherence have been partially blamed; however, genetics have been implicated as well. Providing appropriate therapeutic recommendations could further limit the cases of adverse events from these medications. Up to 3% of pediatric hospital admissions are attributed to asthmatic adverse reactions, ranging from headaches to adrenal suppression [9]. With widespread intra-variability among medication responses, pharmacogenomics has an emerging place in asthmatic treatment. Groundbreaking discoveries in allele variations and polymorphisms, such as single nucleotide polymorphisms (SNPs), provide opportunities for personalized treatment. Pharmacogenomics highlights the importance of optimizing a patient’s response to drug therapy while minimizing adverse reactions. Specifically, breakthrough research completed in 2014 within Cystic Fibrosis patients has allowed therapeutic recommendations to be made for those with the G551D-CFTR variant [10].
Although asthma affects both children and adults, most studies have looked more closely at children, since environmental (i.e., workplace) and social (i.e., smoking) factors are minimized in this patient population. However, there have been no clinically relevant findings that have warranted specific therapeutic recommendations for any asthmatic patient population.

2. Inhaled Corticosteroids (ICS)

Depending on age and severity, the GINA guidelines recommend using ICS monotherapy, or in combination as the preferred controller in addition to a rescue inhaler. ICS are commonly prescribed to treat asthma and, to an extent, COPD. Highly effective in reducing inflammation, ICS can significantly improve asthma symptoms and reduce morbidity in both children and adults. The mechanism of action involves decreasing inflammatory mediators such as mast cells, cytokines, and enzymes such as COX-2. Inhalation routes allow for minimal systemic absorption; thus, efficacy and safety are robust. However, side effects are not negligible, especially when used in children for an extended period. Osteoporosis, glaucoma, and metabolic disturbances are possible adverse events of systemic exposure (Figure 1).
/media/item_content/202202/621832cf53abbjor-02-00003-g002.pngFigure 1. ICS Mechanism of Action. Adapted from [11].
Tantisira conducted a GWAS in 2011 and identified the glucocorticoid-induced transcript 1 (GLCCI1) gene and the SNPs, rs37972 and rs37973 (Table 1) [12]. Non-Hispanic white children selected from the CAMP study were given budesonide, and the response was measured by the change in FEV1 from baseline. Although little is known about GLCCI1, those homozygote for the mutant T allele at SNP, rs37972, yielded a poorer response compared to those who were heterozygote (CT) or homozygote (CC) (OR, 2.36; 95% CI, 1.27–4.41) [12]. Additionally, linkage disequilibrium was found with the SNP, rs37973 (r2 = 0.99). Individuals that were homozygote for the wild-type A allele had a better response to budesonide compared to those homozygotes for the mutant G allele (3.2 ± 1.6% vs. 9.4 ± 1.1% increase in FEV1) [12]. Similar findings were seen in a trial conducted by Thompson et al. [13]. Included in that study were 402 European children on long-term ICS treatment (>6 months). Higher steroid doses and increased hospitalization were seen in SNP, rs37973, homozygous for the mutant allele compared to those heterozygous or homozygous wild-type [13]. Unlike Tantisira [12], Vijverberg saw no association with individuals having SNP, rs37972 and ICS response in Northern European children [14]. Additionally, Vijverberg utilized hospital visits and oral steroid use as markers for exacerbation and concluded that the mutant T allele was not associated with an increased risk when treated with budesonide [14]. In contrast, Huang et al. found associations in the GLCCI1 gene in 263 Chinese children. SNPs, rs37969 GG, rs37972 CC, and rs37973 AA produced favorable changes measured by maximal mid-expiratory flow (p ≤ 0.05) [15]. Stress-induced phosphoprotein 1 (STIP1) was also explored here and was shown to suppress inflammatory mediators. Although a significant association between SNP rs2236647 CC and the risk of developing asthma was found, there was no association with any SNP and ICS response [15].
Table 1. ICS and genetic variations.
Study Population Gene Medication Measurement Results
Tantisira [12] White GLCCI1 Budesonide Change in FEV1 from baseline
CYP3A4 *22 produced favorable response
Stockman
[
23
]
White
CYP3A4, CYP3A5, and CYP3A7 Beclomethasone Asthma control scores CYP3A5 *3/*3 produced favorable response
MMEF = maximal mid-expiratory flow.
It was hypothesized that histone deacetylase I and 2 (HDAC1, HDAC2) play a positive role in airway responsiveness and inflammation. Kim studied 35 adults and 70 children with the HDAC1 SNP, rs1741981 [16]. Bronchodilation was measured as a % change in FEV1 from baseline [16]. Adults with the CC genotype produced diminished responses compared to the CT or TT genotypes when administered systemic corticosteroids (p = 0.018). The same was true for the children given inhaled corticosteroids. Those with the CC genotype had a FEV1 of 14.1% compared to either the CT or TT (19.4%, p = 0.035).
The corticotropin-release hormone (CRH) is a known mediator to stress and its corresponding receptor, corticotropin-releasing hormone receptor 1 (CRHR1), is hypothesized to have a role in ICS response [17]. In comparison to the unfavorable responses seen in the GLCCI1 variants, Tantisira observed an increase in response in those with the CRHR1 variants among three cohorts of both children and adults treated with an ICS. Response was measured by dFEV1 over a span of eight weeks in the CAMP replication study. Those with the rs242941 mutant TT genotypes displayed a change of 17.80 + 6.77 in FEV1 compared to a change of 7.57 + 1.50 in those with the wild-type CC. This was not seen in the initial adult study treated with flunisolide. SNP, rs1876828 variant, was also associated with triamcinolone responses in the adult replication study but was statistically insignificant in children [15].
Variants in the T-box transcription factor (TBX21), which encodes for transcription factor T-bet, also displayed improvements in ICS response. Children with glutamine at amino acid position 33 in place of histidine (rs2240017) displayed better PC20 [18]. PC20 is the provocative concentration resulting in a 20% drop of FEV1 post methacholine challenge. After four years, PC20 for the 33Q individuals given budesonide was measured to be 27.7 mg/mL, placing them in the non-asthmatic range [18]. Tantisira also conducted a study with a focus on the Fc fragment of IgE low affinity II receptor (FCER2) gene [19]. FCER2 encodes for CD23, causing IgE mediated responses which have been associated with severe asthmatic exacerbations. In this study, 311 Caucasian children were assigned to inhaled budesonide and observed over four years. The SNPs identified to be associated with increased IgE levels and exacerbations were: rs4996974, rs7249320, and rs28364072. Children with the SNP, rs28364072, homozygous for the mutant C allele were at a higher risk of severe exacerbations in both African American and Caucasian populations (HR 3.08 and 3.95, respectively) [19]. Koster replicated these findings in two pediatric cohorts treated with ICS. Children’s homozygotes for the variant C allele had a higher risk of severe exacerbations (OR 2.38, 95% CI 1.47–3.85, p = 0.0004), increase in hospital visits (OR 1.91, 95% CI 1.08–3.40, p = 0.03), and were more likely to use higher ICS doses (OR 2.46, 95% CI 1.38–4.39, p = 0.002 [20]. These findings support the need for earlier detection of FCER2 polymorphisms to identify those resistant to steroid treatment and provide timely anti-IgE treatment.
Located on chromosome 5q31-q32, nuclear receptor subfamily 3, group C, member 1 (NR3C1) is a protein-coding gene for glucocorticoid receptors. Keskin studied 82 children with a mean age of 9.6, given inhaled fluticasone propionate specifically evaluating the role of NR3C1 [21]. Of the 82 children, 26 had the rs41423247, GG genotype and displayed a better response compared to those with the CG or CC variations, measured by FEV1 (24.2% vs. 7.9%, p = 0.006) [21]. Stockman also conducted a study involving 734 Caucasian children receiving inhaled fluticasone propionate. Variations among cytochrome p450 (CYP) 3A4, 3A5, and 3A7, which are involved in fluticasone metabolism, were assessed for symptom control using the asthma control score. CYP3A5 and CYP3A7 were not found to have an association, however, CYP3A4 *22 children displayed better asthma control due to the reduced activity of the metabolic enzyme, leading to increased therapeutic outcomes [22]. These findings were not seen in a follow-up study of 64 children treated with beclomethasone [23]. They observed that children with CYP3A5 *3/*3, commonly found among Caucasian populations, displayed better asthma control, compared to either *1/*1 or *1/*3 variations [23]. Pharmacogenomics testing on these CYP enzymes has the potential to provide guidance on future regimens. Children with the CYP3A4 *1/*1 or *1/*3 variation may be advised to use a non-beclomethasone medication, such as budesonide, as their initial ICS. Similarly, those with the CYP3A4 *22 variation may be advised to start therapy with fluticasone.

3. Leukotriene Modifiers (LTM)

Leukotrienes are involved in inflammatory processes and bronchoconstriction, both of which are implicated in asthmatic symptoms. Leukotriene modifiers are considered second line after ICS and LABA for chronic asthma according to the GINA guidelines [3]. Administered orally, these LTMs include zileuton, montelukast, and zafirlukast which are subsequently classified into leukotriene synthesis inhibitors or leukotriene receptor antagonists. Zileuton inhibits the 5-lipoxygenase (5-LO) enzyme, halting the conversion of arachidonic acid into LTA4. Montelukast, zafirlukast, and pranlukast are cysteinyl-leukotriene receptor (CysLTR) inhibitors, antagonizing the effects of LTC4, LTD4, and LTE4 [24][25].
Similar to bronchodilators and ICS, limitations of leukotriene modifiers are highlighted by genetic variations, emphasizing inter-patient variability leading to exacerbated symptoms [26][27]. In addition, nearly half of the side effects in children taking a LTM are attributed to psychiatric disturbances such as hallucinations and agitation [25]. Genes such as arachidonate 5-lipoxygenase (ALOX5) and cysteinyl-LTs (CysLTs) previously identified and replicated in adult studies have not yet been fully confirmed in children. Identifying variants associated with positive leukotriene modifier response can further benefit children who cannot gain symptom control with ICS or beta agonists.

3.1. Genes That Affect Montelukast Response

Montelukast, favored in the pediatric community for its once-a-day dosing, is an oral medication for chronic asthma and exercise-induced bronchoconstriction (EIB). It binds to the CysT1 receptor (CysLTR1), antagonizing the effects of LTD4, and decreasing bronchoconstriction [27].
Both pharmacodynamic and pharmacokinetic studies have shown to potentially impact montelukast responsiveness in children (Table 2).
Table 2. Montelukast and genetic variations.
Study Population Gene Measurement Results
rs37972 TT and rs37973 G allele variants showed unfavorable responses
Kim [28] Korean TBXA2 FEV1 Combination of +795 CT/CC and +924 TT showed unfavorable response
Thompson [13] European GLCCI1 ICS Exacerbation (hospital visits and oral steroid use) rs37973 G allele showed unfavorable response
Vijverberg [14] Europe GLCCI1 Budesonide Exacerbation (emergency room visits, hospital visits, oral steroid use) No association found at rs37972
Huang [15] Chinese GLCCI1 ICS MMEF rs37969, rs37972, and rs37973 produced favorable response.
Kim [16] Korean HDAC1
Klotsman [29] Multiethnic ALOX5

CystLTR2

LTC4S		 PEF

PEF

FEV1 and PEF		 rs4987105 TT and rs4986832 AA variants showed favorable outcomes

rs912277 TT and rs912278 TC variants produced favorable response

No association found at rs730012
Telleria [30] Spain ALOX5 % change in FEV1, exacerbations, and rescue inhaler need rs59439148 5/5 and 5/4 copies showed favorable outcomes
Kang [31] Korean LTC4S

PTGDR		 ≥10% increase in FEV1 post exercise challenge No significance at rs730012

rs803010 TT produced favorable response		 ICS % change in FEV1 pre- and post-bronchodilator rs1741981 CT and TT produced favorable response
Lee [32] Korean LTC4S

CystLTR1		 >10% increase in FEV1 post exercise challenge No significance at SNP rs730012

No significance found		 Tantisira [17]
Whelan [33]Caucasians CRHR1 Budesonide % change in FEV1 from baseline African American and Caucasianrs242941T produced favorable response
LTC4S FENO rs730012 AC produced favorable response Tantisira [18] Multiethnic TBX21 Budesonide % change in FEV1 and PC20 rs2240017Q produced favorable response
p = 0.063) [28]. Responders were defined as >10% in FEV1 after montelukast treatment. In addition, those with both the TBXA2R +795 CT or CC and +924 TT variation were less likely to respond to montelukast treatment (OR 3.67, p = 0.041) [28].
In comparison, Klotsman found a statistically significant association of responsiveness in the ALOX5 variants among children 15 years of age and older. ALOX5 encodes for 5-lipoxygenase (5-LO) and is found on chromosome 10q11.21 [36]. 5-LO is involved in the conversion of arachidonic acid into LTA4 and is the rate limiting step in leukotriene synthesis (Figure 2). Two out of five variants were significantly associated with a positive response to montelukast. Those with the SNP rs4987105 TT genotype produced a mean PEF of 94.8 while those with CC genotypes were 33.7 (p = 0.01). Those with the SNP rs4986832 AA genotype produced a mean PEF of 102.4 while those with the GG genotype were 34.9 (p = 0.01) [29]. Conversely, Telleria et al. studied the promoter region of the ALOX5 gene. Five copies of the transcription factor binding sequence GGGCGG (rs59439148) were recognized as the major allele, with variants hypothesized to produce reduced activity [30]. They found greater improvements with homozygotes wild type (5/5) and heterozygotes (5/4), compared to homozygote variants (4/4) after 6 months of montelukast treatment. Those with the 4/4 repeats displayed higher rates of exacerbations, worsening FEV1, and greater need for rescue inhaler compared to those with the 5/5 or 5/4 repeats (p ≤ 0.05) [30].
/media/item_content/202202/621832ffdb28ajor-02-00003-g003.pngFigure 2. Leukotriene Modifiers Mechanism of Action. Adapted from [36].
Similar to CystLTR1, cysteinyl- leukotriene (CystLT) receptor 2 (CysLTR2) have recently been found on smooth muscle cells. Although the variant function of this gene has yet to be identified, it has been associated with asthmatic treatment response. SNPs, rs912277 TC and rs912278 CC, were found to produce greater PEF (p = 0.021 and p = 0.02, respectively) in a study done by Klotsman [29]. Participants were at least 15 years of age and observed over 12 weeks. TT genotypes in both SNPs produced a mean PEF of 38.8 and 29.1, respectively. In the same study, they assessed leukotriene C4 synthase (LTC4S). LTC4S converts leukotriene A4 to leukotriene C4, increasing CysLT levels contributing to asthmatic inflammation (Figure 2). However, no association was found in montelukast treatment in either FEV1 or PEF in SNP, rs730012 [29]. Furthermore, Kang could not establish statistical significance in those with the LTC4S polymorphisms between responders and non-responders (p = 0.702) in 100 Korean asthmatic children [31]. Lee claimed that montelukast responsiveness is associated with total IgE and PC20 levels, opposed to FEV1 [32]. This research also observed CysLTR1 variations with exercise-induced bronchoconstriction (EIB). However, no correlation to montelukast responsiveness, measured by >10% increase in FEV1 post exercise challenge, was found [32]. Whelan investigated 13 children, ages 10–16 and found a positive correlation in montelukast responsiveness and LTC4S. Statistical significance in those with the LTC4S AC genotype produced a greater decrease in fraction of exhaled nitric oxide (FENO) (slope −3.13%/day), which was correlated with a decrease in airway inflammation. Those with the AA genotype did not produce any noticeable change in FENO, suggesting montelukast use in these patients may not be beneficial [33].
A study by Kang on 10 Korean asthmatic children investigated prostaglandin D2 receptor (PTGDR), a derivative of arachidonic acid implicated in eosinophilia migration [31]. Over the span of eight weeks children receiving montelukast with the rs803010 TT genotype had a greater FEV1 fall post-exercise challenge compared to those with the TC or CC genotype (63.8% vs. 36.2% p = 0.038). No difference in response was found when analyzing both PTGDR and LTC4S variants [31].
Lipworth observed 62 children with ADRB2 Arg16Arg variants and found montelukast reduced school absences and symptoms compared to those treated with salmeterol. All children also received inhaled fluticasone throughout the one-year study. It was concluded that the use of montelukast and an ICS may be more beneficial than the recommended ICS and LABA combination [37] (Table 3).
Table 3. Montelukast Combination and ADRB2.
Study Population Gene Medication Measurement Results
Lipworth [37] Scotland ADRB2 Fluticasone + montelukast or salmeterol + fluticasone School absences, FEV1, asthma symptoms Arg16Arg produced favorable responses to fluticasone and montelukast
Mougey
[
34
]
Multiethnic SLCO2B1 Asthma symptom utility index (ASUI) rs12422149 GG produced favorable response

No association at rs2306168
Tantisira [19] Multiethnic FCER2 Budesonide Exacerbations (ER visits or hospitalization) rs28364072 CC produced unfavorable response
Li [35] Chinese SLCO2B1CYP2C8 Drug clearance Koster [20] European FCER2 ICS, ICS + salmeterol, ICS + salmeterol + montelukast Exacerbations (hospital visits and/or oral steroid use) rs28364072 CC produced unfavorable response
Decreased clearance in rs12422149 GG No association found Keskin [21] Turkey NR3C1 Fluticasone FEV1 improvement at 4 h rs41423247 GG produced favorable response
Stockman [22] Whites CYP3A4, CYP3A5, and CYP3A7 Fluticasone Asthma control scores
Thromboxane A2 (TBXA2), an arachidonic acid derivative, binds to the thromboxane A2 receptor (TBXA2R) and causes pulmonary smooth muscle constriction and platelet aggregation. To determine an association between the TBXA2R gene and LTM response, Kim et al. conducted a study on 695 Korean children with exercise-induced bronchospasms given montelukast. They found that those with the TBXA2R +795 CC or CT variations were 2.5 times more likely to be unresponsive to treatment (
Organic anion transporter polypeptide 2B1 (OATP2B1) are drug transporters found in the liver, intestine, and kidney and are responsible for reuptake of various substrates. This transporter is encoded by the gene solute carrier organic anion transporter family member 2B1 (SLCO2B1). OATP2B1 SNPs rs12422149 and rs2306168 have been associated with montelukast absorption [34]. Mougey utilized the Asthma Symptoms Utility Index (ASUI) to measure drug responsiveness and found that those with the rs12422149 GG genotype demonstrated greater improvement at three months and six months compared to the those with the AG genotype [34]. Similarly, a study by Li with 50 Chinese children with an average age of 4.4 years old found lower montelukast clearance in the SLCO2B1 rs12422149 GG genotype compared to the GA and AA (0.77 ± 0.21 vs. 0.94 ± 0.26, p = 0.020) [35]. Those with the GG genotype displayed better responsiveness to montelukast due to lower drug clearance leading to increased plasma concentrations. Li also examined CYP2C8 variations, however no association was found with montelukast clearance in Chinese children [35]. These results may favor genetic testing to identify SLCO2B1, rs12422149 GG variants, which presumably should see the greatest effect from monteluakast treatment among LTM medications [38]. Those without the SLCO2B1, rs12422149 GG variants may see better efficacy on a different LTM [39].

3.2. Genes Affecting Other Leukotriene Modifier Responses

Zileuton is a 5-LO inhibitor that leads to decreased leukotriene synthesis, inflammation, and bronchoconstriction (Figure 2). Those on zileuton should monitor their ALT regularly [40]. Data on zileuton responsiveness is scarce as most studies utilized montelukast as the drug of choice. Tcheurekdjlan looked at Puerto Rican and Mexican youths with an average age of 12.3 taking a leukotriene modifier and albuterol. Bronchodilator responsiveness, measured by FEV1, was found to be greater in those taking LTM compared to those did not (p = 0.001) [41]. In addition, leukotriene A4 hydrolase (LTA4H) was investigated. LTA4H converts LTA4 to LTB4, which contributes to neutrophilic asthma characterized by severe airway obstruction. The LTA4H SNP rs2540491 minor A allele produced a change of 7–10% in FEV1 compared to the major G allele which produced a change of −0.31% in FEV1 (Table 4). These results were seen in the Puerto Rican population, but not in the Mexican population. The LTA4H SNP rs2540487 GA heterozygotes also produced a change of more than 10% in FEV1 (p < 0.001) compared to homozygotes major or minor (2.5 % change in FEV1, p = 0.180 and 0.679, respectively) [41]. Arachidonate 5-lipoxygenase activating protein (ALOX5AP) modulates downstream leukotriene synthesis along with ALOX5, converting arachidonic acid into leukotriene A4 (Figure 2). No association was found between ALOX5AP, rs10507391 and rs955196 variants with leukotriene modifier bronchodilation. Interactions between LTA4H, ALOX5AP, and their variants were also analyzed for bronchodilation. The presence of ALOX5AP, rs10507391 major A allele and LTA4H minor allele variants contributed to bronchodilation, whereas the presence of ALOX5AP, rs9551963 minor C allele and LT4AH minor allele variants contributed to bronchodilation. These findings were significant in Puerto Rican populations but not Mexican populations [41].
Table 4. Leukotriene Modifier and Genetic Variants.
Study Population Gene Medication Measurement Results
Tcheurekdjlan [41] Mexican and Puerto Ricans LTA4H

ALOX5AP		 Albuterol + leukotriene modifiers (montelukast, zafirlukast, and zileuton) % change in FEV1 pre and post bronchodilator LTA4H rs2540491 A variants and

rs2540487 GA variants produced favorable response

No association of ALOX5AP variants alone

rs10507391 A allele and rs9551963 C allele magnifies LTA4H response

References

  1. Centers for Disease Control and Prevention. 2019 National Health Interview Survey (NHIS) Data. Available online: https://www.cdc.gov/asthma/nhis/2019/data.htm/ (accessed on 25 October 2021).
  2. Weiss, S.T.; Litonjua, A.A.; Lange, C.; Lazarus, R.; Liggett, S.B.; Bleecker, E.R.; Tantisira, K.G. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics 2006, 6, 311–326.
  3. The Global Asthma Report 2018; Global Asthma Network: Auckland, New Zealand. 2018. Available online: globalasthmareport.org (accessed on 31 January 2022).
  4. Nurmagambetov, T.; Kuwahara, R.; Garbe, P. The Economic Burden of Asthma in the United States 2008-2013. Ann. Am. Thorac Soc. 2018, 15, 348–356.
  5. Centers for Disease Control and Prevention. Asthma-Related Missed School Days among Children Aged 5–17 Years. Available online: https://www.cdc.gov/asthma/asthma_stats/missing_days.htm/ (accessed on 20 August 2021).
  6. Dharmage, S.C.; Perret, J.L.; Custovic, A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019, 18, 246.
  7. Global Initiative for Asthma. Global Initiative for Asthma—GINA. Available online: https://ginasthma.org/ (accessed on 2 September 2021).
  8. Gustafsson, P.M.; Watson, L.; Davis, K.J.; Rabe, K.F. Poor asthma control in children: Evidence from epidemiological surveys and implications for clinical practice. Int. J. Clin. Pract. 2006, 60, 321–334.
  9. Gallagher, R.M.; Mason, J.R.; Bird, K.A.; Kirkham, J.J.; Peak, M.; Williamson, P.R.; Nunn, A.J.; Turner, M.A.; Pirmohamed, M.; Smyth, R.L. Adverse drug reactions causing admission to a paediatric hospital. PLoS ONE 2012, 7, e50127.
  10. Clancy, J.P.; Johnson, S.G.; Yee, S.W.; McDonagh, E.M.; Caudle, K.E.; Klein, T.E.; Cannavo, M.; Giacomini, K.M. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin. Pharmacol. Ther. 2014, 95, 592–597.
  11. Barnes, P.J. Inhaled Corticosteroids. Pharmaceuticals 2010, 3, 514–540.
  12. Tantisira, K.G.; Lasky-Su, J.; Harada, M.; Murphy, A.; Litonjua, A.A.; Himes, B.E.; Lange, C.; Lazarus, R.; Sylvia, J.; Klanderman, B.; et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 2011, 365, 1173–1183.
  13. Thompson, B.; Hawcutt, D.; Carr, D.; Jorgensen, A.; Smyth, R.; Pirmohamed, M. S31 variation at GLC1CI1: Association with increased steroid dose but not adrenal suppression in asthmatic children. Thorax 2012, 67 (Suppl. 2), A17.
  14. Vijverberg, S.J.; Tavendale, R.; Leusink, M.; Koenderman, L.; Raaijmakers, J.A.; Postma, D.S.; Koppelman, G.H.; Turner, S.W.; Mukhopadhyay, S.; Palmer, C.N.; et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics 2014, 15, 799–806.
  15. Huang, J.; Hu, X.; Zheng, X.; Kuang, J.; Liu, C.; Wang, X.; Tang, Y. Effects of STIP1 and GLCCI1 polymorphisms on the risk of childhood asthma and inhaled corticosteroid response in Chinese asthmatic children. BMC Pulm. Med. 2020, 20, 303.
  16. Kim, M.H.; Kim, S.H.; Kim, Y.K.; Hong, S.J.; Min, K.U.; Cho, S.H.; Park, H.W. A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics. Korean J. Intern. Med. 2013, 28, 708–714.
  17. Tantisira, K.G.; Lake, S.; Silverman, E.S.; Palmer, L.J.; Lazarus, R.; Silverman, E.K.; Liggett, S.B.; Gelfand, E.W.; Rosenwasser, L.J.; Richter, B.; et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 2004, 13, 1353–1359.
  18. Tantisira, K.G.; Hwang, E.S.; Raby, B.A.; Silverman, E.S.; Lake, S.L.; Richter, B.G.; Peng, S.L.; Drazen, J.M.; Glimcher, L.H.; Weiss, S.T. TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl. Acad. Sci. USA 2004, 101, 18099–18104.
  19. Tantisira, K.G.; Silverman, E.S.; Mariani, T.J.; Xu, J.; Richter, B.G.; Klanderman, B.J.; Litonjua, A.A.; Lazarus, R.; Rosenwasser, L.J.; Fuhlbrigge, A.L.; et al. FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy. Clin. Immunol. 2007, 120, 1285–1291.
  20. Koster, E.S.; Maitland-van der Zee, A.H.; Tavendale, R.; Mukhopadhyay, S.; Vijverberg, S.J.; Raaijmakers, J.A.; Palmer, C.N. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 2011, 66, 1546–1552.
  21. Keskin, O.; Uluca, Ü.; Birben, E.; Coşkun, Y.; Ozkars, M.Y.; Keskin, M.; Kucukosmanoglu, E.; Kalayci, O. Genetic associations of the response to inhaled corticosteroids in children during an asthma exacerbation. Pediatr. Allergy Immunol. 2016, 27, 507–513.
  22. Stockmann, C.; Fassl, B.; Gaedigk, R.; Nkoy, F.; Uchida, D.A.; Monson, S.; Reilly, C.A.; Leeder, J.S.; Yost, G.S.; Ward, R.M. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J. Pediatr. 2013, 162, 1227–1227, 1227.e1–2.
  23. Stockmann, C.; Reilly, C.A.; Fassl, B.; Gaedigk, R.; Nkoy, F.; Stone, B.; Roberts, J.K.; Uchida, D.A.; Leeder, J.S.; Sherwin, C.M.; et al. Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. J. Allergy Clin. Immunol. 2015, 136, 505–507.
  24. Lima, J.J. Treatment heterogeneity in asthma: Genetics of response to leukotriene modifiers. Mol. Diagn. Ther. 2007, 11, 97–104.
  25. Choi, J. Leukotriene Receptor Antagonists. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554445/ (accessed on 5 November 2021).
  26. Drazen, J.M.; Israel, E.; O’Byrne, P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999, 340, 197–206.
  27. Bäck, M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 2002, 71, 611–622.
  28. Kim, J.H.; Lee, S.Y.; Kim, H.B.; Jin, H.S.; Yu, J.H.; Kim, B.J.; Kim, B.S.; Kang, M.J.; Jang, S.O.; Hong, S.J. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin. Exp. Allergy 2008, 38, 51–59.
  29. Klotsman, M.; York, T.P.; Pillai, S.G.; Vargas-Irwin, C.; Sharma, S.S.; van den Oord, E.J.; Anderson, W.H. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genom. 2007, 17, 189–196.
  30. Telleria, J.J.; Blanco-Quiros, A.; Varillas, D.; Armentia, A.; Fernandez-Carvajal, I.; Jesus Alonso, M.; Diez, I. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir. Med. 2008, 102, 857–861.
  31. Kang, M.J.; Kwon, J.W.; Kim, B.J.; Yu, J.; Choi, W.A.; Shin, Y.J.; Hong, S.J. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J. Hum. Genet. 2011, 56, 284–289.
  32. Lee, S.Y.; Kim, H.B.; Kim, J.H.; Kim, B.S.; Kang, M.J.; Jang, S.O.; Seo, H.J.; Hong, S.J. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA). Clin. Exp. Allergy 2007, 37, 1487–1493.
  33. Whelan, G.J.; Blake, K.; Kissoon, N.; Duckworth, L.J.; Wang, J.; Sylvester, J.E.; Lima, J.J. Effect of montelukast on time-course of exhaled nitric oxide in asthma: Influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol. 2003, 36, 413–420.
  34. Mougey, E.B.; Feng, H.; Castro, M.; Irvin, C.G.; Lima, J.J. Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genom. 2009, 19, 129–138.
  35. Li, Q.; Wang, K.; Shi, H.Y.; Wu, Y.E.; Zhou, Y.; Kan, M.; Zheng, Y.; Hao, G.X.; Yang, X.M.; Yang, Y.L. Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children. Drug Des. Devel. Ther. 2019, 13, 4405–4411.
  36. Mougey, E.; Lang, J.E.; Allayee, H.; Teague, W.G.; Dozor, A.J.; Wise, R.A.; Lima, J.J. ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. Clin. Exp. Allergy 2013, 43, 512–520.
  37. Lipworth, B.J.; Basu, K.; Donald, H.P.; Tavendale, R.; Macgregor, D.F.; Ogston, S.A.; Palmer, C.N.; Mukhopadhyay, S. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin. Sci. (Lond.). 2013, 124, 521–528.
  38. Karonen, T.; Neuvonen, P.J.; Backman, J.T. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br. J. Clin. Pharmacol. 2012, 73, 257–267.
  39. Aquilante, C.L.; Niemi, M.; Gong, L.; Altman, R.B.; Klein, T.E. PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet. Genom. 2013, 23, 721–728.
  40. Bouchette, D.; Preuss, C.V. Zileuton. Available online: https://www.ncbi.nlm.nih.gov/books/NBK448202/ (accessed on 21 August 2021).
  41. Tcheurekdjian, H.; Via, M.; De Giacomo, A.; Corvol, H.; Eng, C.; Thyne, S.; Chapela, R.; Rodriguez-Cintron, W.; Rodriguez-Santana, J.R.; Avila, P.C.; et al. Genetics of Asthma in Latino Americans Study. Genetics of asthma in Latino Americans study. ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. J. Allergy Clin. Immunol. 2010, 126, 853–858.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback